Co-administration of cisplatin and curcumin does not alter mood-associated behaviors

Demir, Enver Ahmet; M, Oz; Mi, Alp; Hs, Gergerlioğlu; Ke, Nurullahoglu; Fh, Yerlikaya

doi:10.4149/bll_2016_021

Cited by 3 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The antidepressant efficacy of curcumin in modulating depressive behavior in different animal models has been shown in a large number of behavioral studies. Most of the studies reported improved performance in the forced swimming test [ 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 ], increased locomotor activity in the open field test [ 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 ], decreased anxiety in the elevated plus maze test [ 57 , 59 , 64 , 65 , 66 ], improved anhedonia in the sucrose preference test [ 51 , 52 , 54 , 56 , 58 , 62 , 67 , 68 , 69 , 70 , 71 , 72 ,…”

Section: Resultsmentioning

confidence: 99%

An Update on the Exploratory Use of Curcumin in Neuropsychiatric Disorders

et al. 2022

View full text Add to dashboard Cite

Curcumin is a polyphenol extracted from the rhizome of the turmeric plant. Beyond its common use as a culinary spice in Eastern Asia, curcumin has been proposed as a therapeutic compound due to its antioxidant, anti-inflammatory and neuroprotective properties. Thus, its efficacy has been evaluated in various inflammatory-based psychiatric disorders, such as schizophrenia, depression, or autism. Our aim is to review those preclinical and clinical studies carried out in psychiatric disorders whose therapeutic approach has involved the use of curcumin and, therefore, to discern the possible positive effect of curcumin in these disorders. Preclinical studies and completed clinical trials of curcumin for psychiatric disorders published from January 2005 to October 2021 were identified through searching relevant databases until 31st October 2021. Sixty-five preclinical studies and 15 clinical trials and open-label studies were selected. Results showed a bias toward studies in depression and, to a lesser extent, schizophrenia. In all disorders, the results were positive in reducing psychiatric deficits. Despite the considerable number of beneficial outcomes reported, the small number of trials and the heterogeneity of protocols make it difficult to draw solid conclusions about the real potency of curcumin in psychiatric disorders.

show abstract

Section: Resultsmentioning

confidence: 99%

An Update on the Exploratory Use of Curcumin in Neuropsychiatric Disorders

et al. 2022

View full text Add to dashboard Cite

show abstract

“…It can coincide with and aggravate existing physical pathologies (2,6,8). On the other side, chronic diseases can also generate depressive disorders (2,9,10). Together with its complications including the aggravation of physical health conditions, depression is a serious public health concern which also creates an important economic burden (10)(11)(12).…”

Section: How Do We Recognize Depression?mentioning

confidence: 99%

Depression in Alzheimer’s Disease: The Roles of Cholinergic and Serotonergic Systems

Demir

Tutuk

Doğan

et al. 2019

Alzheimer’s Disease

View full text Add to dashboard Cite

Although depression and Alzheimer' s disease fundamentally result from distinct pathophysiological events, their coincidence is far from a rare occurrence. In addition to the difficulty in the diagnosis of depression in the patients with a cognitive impairment, care givers and even physicians are mostly unaware that depression and Alzheimer' s disease can coexist. While depression has already a devastating impact on quality of life by itself, coinciding depression and Alzheimer' s disease may advance to a cataclysmic magnitude. This chapter underlines obstacles in the recognition of depression in the Alzheimer' s patients following a brief introduction to the concept of depression. Depression and Alzheimer' s disease appear to intersect in the cholinergic and serotonergic systems which may engender an exquisite strategy in the treatment of both disorders. Therefore, potential cholinergic and serotonergic targets are also emphasized.

show abstract

Potential Role of Curcumin for the Treatment of Major Depressive Disorder

Lopresti

2022

CNS Drugs

View full text Add to dashboard Cite

Curcumin is the major biologically active polyphenolic constituent in the turmeric plant (Curcuma longa) that has been shown to have antioxidant, anti-inflammatory, neuroprotective, anticancer, antimicrobial, and cardioprotective effects. Interest in curcumin as a treatment for mental health conditions has increased and there is an expanding body of preclinical and clinical research examining its antidepressant and anxiolytic effects. In this narrative review, human trials investigating the effects of curcumin for the treatment of depression or depressive symptoms are summarised. Using findings from in vitro, animal, and human trials, possible biological mechanisms associated with the antidepressant effects of curcumin are also explored. To increase the understanding of curcumin for the treatment of depression, directions for future research are proposed. Key PointsEvidence from animal and human trials confirms curcumin is a promising treatment for depression.Curcumin has multiple biological actions that may account for its antidepressant effects.More research is required to increase the understanding of the antidepressant effects of curcumin.

show abstract

Co-administration of cisplatin and curcumin does not alter mood-associated behaviors

Cited by 3 publications

References 11 publications

An Update on the Exploratory Use of Curcumin in Neuropsychiatric Disorders

An Update on the Exploratory Use of Curcumin in Neuropsychiatric Disorders

Depression in Alzheimer’s Disease: The Roles of Cholinergic and Serotonergic Systems

Potential Role of Curcumin for the Treatment of Major Depressive Disorder

Contact Info

Product

Resources

About